Influence of estrogen in non-small cell lung cancer and its clinical implications

摘要: Lung cancer (LC) is the leading cause of death in men worldwide and has significantly increased women. Differences non-small cell lung (NSCLC) behavior, prognosis, response to treatment have been reported by sex hormonal status, with premenopausal women presenting worst prognosis compared postmenopausal men. Additionally, use replacement therapy increases NSCLC mortality; supporting role estrogen signaling pathogenesis LC. The mechanisms which promotes carcinogenesis not fully elucidated. Estrogen, through its receptor, can stimulate LC proliferation, resistance, angiogenesis, migration metastasis. Estrogen also induces expression pro-inflammatory proteins ligands that promote tumor evasion, suggesting might modify microenvironment anti-tumor immune response. Recent reports shown an interaction between epidermal growth factor receptor (EGFR) pathway adenocarcinoma, whence, combined based on tyrosine kinase inhibitors (TKIs) antiestrogen beginning be evaluated. This review focuses differences behavior highlighting receptors prognosis. Due importance development progression we finally discuss potential show results from preclinical clinical trials.